{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:01:10Z","timestamp":1792454470774,"version":"4.5.0"},"reference-count":53,"publisher":"Oxford University Press (OUP)","issue":"Supplement_1","license":[{"start":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T00:00:00Z","timestamp":1738713600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>\u2009<\/jats:title>\n                  <jats:p>The use of mineralocorticoid receptor antagonists (MRAs) in preclinical models of non-diabetic chronic kidney disease (CKD) has consistently shown a beneficial effect by preventing renal structural injury, reducing albuminuria and preserving renal function. In this context, MR activation in non-epithelial cells contributes to renal injury through the activation of inflammatory and fibrotic pathways, increasing oxidative stress and modulating renal hemodynamics. The protective effects of MRAs in animal models of CKD are not restricted to the kidney. Cardiovascular benefits, such as the prevention of cardiac fibrosis, hypoperfusion and vascular calcification, have also been observed. The translation of these preclinical findings into clinical practice has been difficult, mainly due to the lack of clinical studies testing the efficacy of steroidal MRAs in CKD patients due to their contraindication because of an increased risk of hyperkalemia in these patients. Here, we review the latest preclinical evidence showing new mechanisms by which MR inhibition results in beneficial effects against cardiorenal damage in non-diabetic kidney disease. Moreover, we summarize the clinical trials testing the safety and efficacy of steroidal and non-steroidal MRAs in patients with advanced non-diabetic CKD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>PLAIN ENGLISH SUMMARY<\/jats:title>\n                  <jats:p>The mineralocorticoid receptor (MR) is known for its role in the regulation of sodium and potassium balance in the distal tubules of the kidney. However, under pathological conditions the activation of the MR in other renal cell types (including the vasculature and immune cells) leads to harmful effects, damaging the main structural components of the kidney, and ultimately causing renal dysfunction. Over the past 20 years, several studies performed in mouse and rat models of non-diabetic kidney disease have shown that using a specific drug class that inhibits the MR (MR antagonists: MRAs) positively impacts the preservation of the kidney structure and helps to prevent the decline of renal function, thus positioning MRAs as a good therapeutic option against kidney diseases from non-diabetic origin. In addition, the use of MRAs also benefited the cardiovascular system health as shown by improved cardiac structural and functional parameters as well as preventing the calcification of blood vessels. Nevertheless, an important barrier to translating these findings into clinical practice is that the use of MRAs could lead to increased serum potassium levels, particularly in kidney disease patients, an adverse effect that could lead to life-threatening cardiac arrhythmias. In this review, we summarize the latest data in animal models showing new evidences of MR benefits in non-diabetic kidney disease. In addition, we review the clinical trials that evaluated the safety and efficacy of MRAs in patients with advanced non-diabetic kidney disease including those that tested a new generation of MRAs (non-steroidal MRAs) and are expected to reduce the frequency of adverse effects while retaining their renal and cardiovascular benefits.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfae241","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T12:18:48Z","timestamp":1731327528000},"page":"i29-i36","source":"Crossref","is-referenced-by-count":13,"title":["Mineralocorticoid receptor antagonism for non-diabetic kidney disease"],"prefix":"10.1093","volume":"40","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Jaisser","sequence":"first","affiliation":[{"name":"Universit\u00e9 de Lorraine, INSERM Centre d'Investigations Cliniques-Plurith\u00e9matique 1433, UMR 1116, CHRU de Nancy, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT , Nancy 54500 ,","place":["France"]},{"name":"Sorbonne Universit\u00e9, Universit\u00e9 de Paris INSERM, UMRS 1138, Centre de Recherche des Cordeliers, , Paris 75006 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonatan","family":"Barrera-Chimal","sequence":"additional","affiliation":[{"name":"Centre affili\u00e9 \u00e0 l'Universit\u00e9 de Montr\u00e9al Centre de Recherche de l'H\u00f4pital Maisonneuve-Rosemont, Facult\u00e9 de M\u00e9decine, , Montr\u00e9al, Qu\u00e9bec H1T 2M4,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,5]]},"reference":[{"key":"2025020513210043600_bib1","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.kint.2019.02.030","article-title":"Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis","volume":"96","author":"Barrera-Chimal","year":"2019","journal-title":"Kidney Int"},{"key":"2025020513210043600_bib2","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1111\/bph.15734","article-title":"The mineralocorticoid receptor in chronic kidney disease","volume":"179","author":"Barrera-Chimal","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2025020513210043600_bib3","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1146\/annurev-physiol-060821-013950","article-title":"Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases","volume":"84","author":"Barrera-Chimal","year":"2022","journal-title":"Annu Rev Physiol"},{"key":"2025020513210043600_bib4","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2025020513210043600_bib5","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.3390\/pharmaceutics15051373","article-title":"The mineralocorticoid receptor on smooth muscle cells promotes tacrolimus-induced renal injury in mice","volume":"15","author":"Figueroa","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025020513210043600_bib6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/ki.2015.312","article-title":"Deletion of mineralocorticoid receptors in smooth muscle cells blunts renal vascular resistance following acute cyclosporine administration","volume":"89","author":"Amador","year":"2016","journal-title":"Kidney Int"},{"key":"2025020513210043600_bib7","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1093\/ndt\/gfy246","article-title":"Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation","volume":"34","author":"Barrera-Chimal","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2025020513210043600_bib8","doi-asserted-by":"publisher","first-page":"e14448","DOI":"10.14814\/phy2.14448","article-title":"Spironolactone mitigates, but does not reverse, the progression of renal fibrosis in a transgenic hypertensive rat","volume":"8","author":"Leader","year":"2020","journal-title":"Physiol Rep"},{"key":"2025020513210043600_bib9","doi-asserted-by":"publisher","first-page":"109396","DOI":"10.1016\/j.intimp.2022.109396","article-title":"Eplerenone inhibits the macrophage-to-myofibroblast transition in rats with UUO-induced type 4 cardiorenal syndrome through the MR\/CTGF pathway","volume":"113","author":"Han","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"2025020513210043600_bib10","doi-asserted-by":"publisher","first-page":"1283729","DOI":"10.1155\/2022\/1283729","article-title":"Eplerenone prevents cardiac fibrosis by inhibiting angiogenesis in unilateral urinary obstruction rats","volume":"2022","author":"Chang","year":"2022","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2025020513210043600_bib11","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00210-023-02665-5","article-title":"Eplerenone improves hyperglycemia and sympathetic excitation in chronic renocardiac syndrome in rats","volume":"397","author":"Wu","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2025020513210043600_bib12","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.yjmcc.2018.06.008","article-title":"Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice","volume":"121","author":"Bonnard","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"2025020513210043600_bib13","doi-asserted-by":"publisher","first-page":"e032971","DOI":"10.1161\/JAHA.123.032971","article-title":"Non-steroidal mineralocorticoid receptor antagonist finerenone improves diastolic dysfunction in preclincial non-diabetic chronic kidney disease","volume":"13","author":"Lima-Posada","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"2025020513210043600_bib14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1186\/s12882-019-1534-4","article-title":"Spironolactone ameliorates endothelial dysfunction through inhibition of the AGE\/RAGE axis in a chronic renal failure rat model","volume":"20","author":"Wang","year":"2019","journal-title":"BMC Nephrol"},{"key":"2025020513210043600_bib15","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","article-title":"Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress","volume":"9","author":"Gonzalez-Blazquez","year":"2018","journal-title":"Front Pharmacol"},{"key":"2025020513210043600_bib16","doi-asserted-by":"publisher","first-page":"10659","DOI":"10.3390\/ijms231810659","article-title":"Effects of chronic kidney disease on nanomechanics of the endothelial glycocalyx are mediated by the mineralocorticoid receptor","volume":"23","author":"Fels","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025020513210043600_bib17","doi-asserted-by":"publisher","first-page":"F967","DOI":"10.1152\/ajprenal.00669.2014","article-title":"Spironolactone ameliorates arterial medial calcification in uremic rats: the role of mineralocorticoid receptor signaling in vascular calcification","volume":"309","author":"Tatsumoto","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2025020513210043600_bib18","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbrc.2021.10.023","article-title":"Protective effects of spironolactone on vascular calcification in chronic kidney disease","volume":"582","author":"Hammer","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"key":"2025020513210043600_bib19","doi-asserted-by":"publisher","first-page":"5372","DOI":"10.3390\/ijms21155372","article-title":"Beneficial effects of mineralocorticoid receptor antagonism on myocardial fibrosis in an experimental model of the myxomatous degeneration of the mitral valve","volume":"21","author":"Ibarrola","year":"2020","journal-title":"Int J Mol Sci"},{"key":"2025020513210043600_bib20","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1161\/CIRCRESAHA.119.316427","article-title":"A new role for the aldosterone\/mineralocorticoid receptor pathway in the development of mitral valve prolapse","volume":"127","author":"Ibarrola","year":"2020","journal-title":"Circ Res"},{"key":"2025020513210043600_bib21","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1161\/HYPERTENSIONAHA.122.19526","article-title":"Sex-related signaling of aldosterone\/mineralocorticoid receptor pathway in calcific aortic stenosis","volume":"79","author":"Matilla","year":"2022","journal-title":"Hypertension"},{"key":"2025020513210043600_bib22","doi-asserted-by":"publisher","first-page":"11766","DOI":"10.3390\/ijms241411766","article-title":"Esaxerenone inhibits renal angiogenesis and endothelial-mesenchymal transition via the VEGFA and TGF-beta1 pathways in aldosterone-infused mice","volume":"24","author":"Gao","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025020513210043600_bib23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1042\/CS20211075","article-title":"AIM2 inflammasome contributes to aldosterone-induced renal injury via endoplasmic reticulum stress","volume":"136","author":"Wu","year":"2022","journal-title":"Clin Sci (Lond)"},{"key":"2025020513210043600_bib24","doi-asserted-by":"publisher","first-page":"6680","DOI":"10.3390\/ijms23126680","article-title":"Biglycan is a novel mineralocorticoid receptor target involved in aldosterone\/salt-induced glomerular injury","volume":"23","author":"Nakamura","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2025020513210043600_bib25","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1159\/000524940","article-title":"Finerenone reduces renal ROR\u03b3t \u03b3\u03b4 T cells and protects against cardiorenal damage","volume":"53","author":"Luettges","year":"2022","journal-title":"Am J Nephrol"},{"key":"2025020513210043600_bib26","doi-asserted-by":"publisher","first-page":"e157165","DOI":"10.1172\/JCI157165","article-title":"Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists","volume":"134","author":"Abedini","year":"2024","journal-title":"J Clin Invest"},{"key":"2025020513210043600_bib27","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1681\/ASN.0000000000000186","article-title":"Finerenone added to RAS\/SGLT2 blockade for CKD in Alport Syndrome. Results of a randomized controlled trial with Col4a3-\/- mice","volume":"34","author":"Zhu","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"2025020513210043600_bib28","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","article-title":"Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage","volume":"52","author":"Kolkhof","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025020513210043600_bib29","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1159\/000518254","article-title":"Direct blood pressure-independent anti-fibrotic effects by the selective nonsteroidal mineralocorticoid receptor antagonist finerenone in progressive models of kidney fibrosis","volume":"52","author":"Droebner","year":"2021","journal-title":"Am J Nephrol"},{"key":"2025020513210043600_bib30","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2025020513210043600_bib31","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2025020513210043600_bib32","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"on behalf of the FIDELIO-DKD and FIGARO-DKD investigators. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"2025020513210043600_bib33","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/HJH.0000000000003639","article-title":"Mineralocorticoid receptor antagonist treatment in patients with renal insufficiency and the associated risk of hyperkalemia and death","volume":"42","author":"Hedlund Moller","year":"2024","journal-title":"J Hypertens"},{"key":"2025020513210043600_bib34","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ejhf.2740","article-title":"The effects of mineralocorticoid receptor antagonists on cardiovascular outcomes in patients with end-stage renal disease and heart failure","volume":"25","author":"Lin","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2025020513210043600_bib35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.2215\/CJN.15841020","article-title":"Efficacy and safety of mineralocorticoid receptor antagonists in kidney failure patients treated with dialysis: a systematic review and meta-analysis","volume":"16","author":"Chen","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025020513210043600_bib36","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","article-title":"Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial","volume":"95","author":"Charytan","year":"2019","journal-title":"Kidney Int"},{"key":"2025020513210043600_bib37","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","article-title":"A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients","volume":"95","author":"Hammer","year":"2019","journal-title":"Kidney Int"},{"key":"2025020513210043600_bib38","article-title":"ALdosterone antagonist chronic HEModialysis interventional survival trial (ALCHEMIST): primary results","volume-title":"Paper presented at: American Society of Nephrology Kidney Week 2023, 1\u20135 November","author":"Rossignol.","year":"2023"},{"key":"2025020513210043600_bib39","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000368268","article-title":"Impact of aldosterone on osteoinductive signaling and vascular calcification","volume":"128","author":"Lang","year":"2014","journal-title":"Nephron Physiol"},{"key":"2025020513210043600_bib40","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure.","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2025020513210043600_bib41","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2025020513210043600_bib42","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2025020513210043600_bib43","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2025020513210043600_bib44","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.jchf.2022.06.010","article-title":"Steroidal MRA across the spectrum of renal function: a pooled analysis of RCTs","volume":"10","author":"Ferreira","year":"2022","journal-title":"JACC Heart Fail"},{"key":"2025020513210043600_bib45","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.2635","article-title":"Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure","volume":"24","author":"Vaduganathan","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2025020513210043600_bib46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000534366","article-title":"Effects of mineralocorticoid receptor antagonists for chronic kidney disease: a systemic review and meta-analysis","volume":"55","author":"Yuan","year":"2024","journal-title":"Am J Nephrol"},{"key":"2025020513210043600_bib47","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"key":"2025020513210043600_bib48","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"2025020513210043600_bib49","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2215\/CJN.0000000000000439","article-title":"Effect of spironolactone on kidney function in kidney transplant recipients: a randomized placebo-controlled clinical trial","volume":"19","author":"Mortensen","year":"2024","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025020513210043600_bib50","doi-asserted-by":"publisher","first-page":"sfad249","DOI":"10.1093\/ckj\/sfad249","article-title":"Additive effects of dapagliflozin and finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial","volume":"17","author":"Marup","year":"2024","journal-title":"Clin Kidney J"},{"key":"2025020513210043600_bib51","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized cross-over clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J Am Soc Nephrol"},{"key":"2025020513210043600_bib52","doi-asserted-by":"publisher","first-page":"e073831","DOI":"10.1136\/bmjopen-2023-073831","article-title":"Potassium canrenoate in brain-dead organ donors: a randomised controlled clinical trial protocol (CANREO-PMO)","volume":"13","author":"Belarif","year":"2023","journal-title":"BMJ Open"},{"key":"2025020513210043600_bib53","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s13063-018-2956-1","article-title":"EPURE transplant (Eplerenone in Patients Undergoing Renal Transplant) study: study protocol for a randomized controlled trial","volume":"19","author":"Girerd","year":"2018","journal-title":"Trials"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i29\/61766377\/gfae241.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/40\/Supplement_1\/i29\/61766377\/gfae241.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T13:22:26Z","timestamp":1738761746000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/40\/Supplement_1\/i29\/8002186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":53,"journal-issue":{"issue":"Supplement_1","published-online":{"date-parts":[[2025,2,5]]},"published-print":{"date-parts":[[2025,2,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfae241","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2025,1]]}}}